News Articles

First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial SIOUX FALLS, S.D. -Thursday, January 11th 2018 [ar]

(BUSINESS WIRE) -- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced its anti-MERS immunotherapy (SAB-301) appears safe in a Phase I Clinical Trial. Results of the study, sponsored, funded and conducted by National Institutes of Health (NIH) were...

SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report BETHESDA, Md. & SIOUX FALLS, S.D. -Wednesday, September 21st 2016 [ar]

(BUSINESS WIRE)-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine™), was identified as of one of the six most meritorious proposals...

SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment SIOUX FALLS, S.D. -Thursday, August 25th 2016 [ar]

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today that it has been awarded a contract for up to $5.3 million by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant...

Phase I Clinical Trials Underway for First MERS Treatment SIOUX FALLS, S.D. -Thursday, August 11th 2016 [ar]

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today that Phase I Clinical Trials are underway for its human antibody treatment (SAB-301) for MERS-CoV. The goal of the study–sponsored, funded and conducted by National Institutes...